Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumors
Academic Article
Publication Date:
2009
Iris type:
1.1 Articolo in rivista
List of contributors:
Gregorc, V.; Santoro, A.; Bennicelli, E.; Punt, Cja; Citterio, G.; Timmer Bonte, Jnh; Caligaris Cappio, F.; Lambiase, A.; Bordignon, Claudio; van Herpen, Cml
Published in: